Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.70 |
| ▸ | TLR8 | Q9NR97 | 14/20 | 0.70 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5511655 | 0.92 | TLR7 (0.69) | TLR7TLR8NUDT1 | |
| SCHEMBL5511648 | 0.92 | TLR7 (0.69) | TLR7TLR8NUDT1 | |
| SCHEMBL4537459 | 0.91 | TLR7 (0.70) | TLR7TLR8NUDT1 | |
| SCHEMBL4531126 | 0.91 | TLR7 (0.70) | TLR7TLR8NUDT1 | |
| SCHEMBL17190811 | 0.88 | TLR7 (0.72) | TLR7TLR8NUDT1 | |
| SCHEMBL4533093 | 0.87 | TLR7 (0.75) | TLR7TLR8NUDT1 | |
| SCHEMBL4535615 | 0.85 | TLR7 (0.75) | TLR7TLR8NUDT1 | |
| SCHEMBL4530118 | 0.84 | TLR7 (0.68) | TLR7TLR8NUDT1 | |
| SCHEMBL17181369 | 0.84 | TLR7 (0.83) | TLR7TLR8NUDT1 | |
| SCHEMBL3867611 | 0.83 | TLR7 (0.66) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658666-B2 | Substituted imidazoquinolines and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658666-B2 | Substituted imidazoquinolines and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658666-B2 | Substituted imidazoquinolines and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-02-25 | — | — | US | disclosed |
| US-20090099161-A1 | Substituted Imidazoquinolines and Imidazonaphthyridines | COLEY PHARMACEUTIAL GROUP, INC. (NY) | 2009-04-16 | — | — | US | disclosed |
| US-20090099161-A1 | Substituted Imidazoquinolines and Imidazonaphthyridines | COLEY PHARMACEUTIAL GROUP, INC. (NY) | 2009-04-16 | — | — | US | disclosed |
| US-20090099161-A1 | Substituted Imidazoquinolines and Imidazonaphthyridines | COLEY PHARMACEUTIAL GROUP, INC. (NY) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099161-A1 | Substituted Imidazoquinolines and Imidazonaphthyridines | IL2, EIF2AK2, IFNG | TLR7 35/4885TLR8 90/4885NUDT1 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.